MiNK therapeutics starts randomized phase 2 trial for lung injury therapy
Go back to MiNK therapeutics starts randomized phase 2 trial for lung injury therapy| (NASDAQ: INKT) | Delayed: 12.02 -0.32 (2.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.34 | 52 Week High | $ | |||
| Open | $12.55 | 52 Week Low | $ | |||
| Day High | $12.68 | P/E | N/A | |||
| Day Low | $11.80 | EPS | $ | |||
| Volume | 28,191 | |||||
